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Evidence for a Pathophysiological Role of
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Thomas Tu¨ting1 and Jo¨rg Wenzel1
Type I IFNs (IFNa/b) have been shown to have a central role in the pathophysiology of lupus erythematosus (LE).
The recently discovered type III IFNs (IFNl1/IL29, IFNl2/IL28a, IFNl3/IL28b) share several functional similarities with
type I IFNs, particularly in antiviral immunity. As IFNls act primarily on epithelial cells, we investigated whether type
III IFNs might also have a role in the pathogenesis of cutaneous LE (CLE). Our investigations demonstrate that IFNl
and the IFNl receptor were strongly expressed in the epidermis of CLE skin lesions and related autoimmune
diseases (lichen planus and dermatomyositis). Significantly enhanced IFNl1 could be measured in the serum of
CLE patients with active skin lesions. Functional analyses revealed that human keratinocytes are able to produce
high levels of IFNl1 but only low amounts of IFNa/b/g in response to immunostimulatory nuclear acids, suggesting
that IFNl is a major IFN produced by these cells. Exposure of human keratinocytes to IFNl1 induced
the expression of several proinflammatory cytokines, including CXCL9 (CXC-motiv ligand 9), which drive the
recruitment of immune cells and are associated with the formation of CLE skin lesions. Our results provide
evidence for a role of type III IFNs in not only antiviral immunity but also autoimmune diseases of the skin.
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INTRODUCTION
Inappropriate activation of the type I IFN system (IFNa/b) is a
key feature of lupus erythematosus (LE). Patients with active
systemic LE (SLE) present with flu-like symptoms including
fever and myalgia, which reflect enhanced IFNa serum levels
and correlate positively with SLE disease activity (Dall’era
et al., 2005). Additionally, an exacerbation or aggravation
of SLE has been reported following therapeutic administration
of recombinant IFNa (Ronnblom and Alm, 2003). In cuta-
neous LE (CLE), large numbers of IFN-producing plasmacy-
toid dendritic cells (pDC) can be detected within LE skin
lesions (Blomberg et al., 2001; Farkas et al., 2001). Type I
IFN-inducible chemokines are strongly expressed in CLE skin
lesions and their expression pattern reflects the typical
histological pattern found in the different CLE subsets
(Wenzel et al., 2007). IFN-regulated proinflammatory cyto-
kines, including CXCL9 (CXC-motiv ligand 9) and CXCL10
(CXC-motiv ligand 10), have been shown to drive CLE skin
inflammation (Meller et al., 2005; Wenzel et al., 2005b;
Sontheimer, 2009). It is assumed that apoptotic material
containing immunostimulatory nucleic acids is released
during cell stress reactions and initiates the inflammatory
response in LE. Complexed nucleic acids are internalized by
specialized DCs and stimulate type I IFN-production via Toll-
like receptor (TLR)-dependent and TLR-independent mechan-
isms (Ronnblom and Pascual, 2008; Meyer, 2009).
Recently, a new class of IFNs, the type III or ‘‘l’’ IFNs, has
been discovered as a unique cytokine family with antiviral
function (Kotenko et al., 2003; Sheppard et al., 2003). IFNl1
(IL29), IFNl2 (IL28a), and IFNl3 (IL28b) genetically and
structurally belong to the IL10 family of cytokines. The IFNls
share many functions and mechanisms with type I IFNs,
but they differ substantially with respect to their targeted
cells, with IFNl mainly acting on epithelial cells (Sommereyns
et al., 2008). Accordingly, it has been reported that type III
IFNs are essential for the antiviral response following
viral infection of epithelial cells (e.g., intranasal influenza A
and vaginal herpes simplex virus type 2), whereas intraper-
itoneal infection with hepatotropic viruses evoke an antiviral
response depending on type I IFNs but not on type III IFNs
(Ank et al., 2008).
The type III IFNs bind to a heterodimeric receptor
composed of the IFNl-specific IFNl receptor (IFNlR)
selectively expressed in certain cell types and the ubiqui-
tously expressed IL10Rb, which is also a part of the receptors
for IL10, IL22, and IL26. However, although type I and type
III IFNs bind unrelated heterodimeric receptors, type III IFNs
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display type I IFN-like activity. They also signal through
JAK1/TYK2 (Janus kinase 1/tyrosine kinase 2) tyrosine kinases
and activate STAT1 and STAT2 (signal transducers and
activator of transcription 1 and 2) (Sommereyns et al.,
2008), leading to the expression of ‘‘IFN-stimulated genes’’
such as myxovirus resistance 1, oligoadenylate synthetase,
and interferon-inducible protein 27 (IFI27) that mediate
antiviral effects of both IFN classes (Zhou et al., 2007; Ank
et al., 2008).
Because of the similarity between the type I and the type
III IFN system and the fact that IFNl particularly acts on
epithelial cells, we hypothesized that an activation of the type
III IFN system in keratinocytes might contribute to the
proinflammatory network of CLE.
RESULTS
Expression of IFNk and the IFNkR is enhanced in CLE
skin lesions
Initially, we analyzed skin biopsies taken from untreated
chronic discoid LE (CDLE) and subacute CLE (SCLE) skin
lesions (n¼ 16) and healthy controls (n¼ 6) for the expression
of IFNl and the IFNlR by immunohistochemistry. As shown
in Figure 1, a significant expression of IFNl was detectable in
the lesional epidermis of both CDLE and SCLE patients. In the
dermis, IFNl was expressed by some mononuclear cells and
weakly by endothelial cells. The strongest IFNl expression
was seen in active skin lesions taken from sun-exposed areas
from patients with SCLE. Little expression was detected in
healthy controls. The IFNlR was also strongly expressed in
the epidermis of CLE lesions. Constitutive weak expression
was found in the upper epidermis of healthy controls.
Epidermal expression of IFNl and the IFNlR was not
enhanced in atopic dermatitis and only weakly in psoriasis,
but significantly elevated in dermatomyostis and lichen
planus skin samples.
Elevated IFNk1 serum levels are found in patients
with active CLE
We next investigated IFNl1-serum levels in patients with
active CLE (CDLE and SCLE) by ELISA. As shown in Figure 2a,
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Figure 1. Expression of IFNk and the IFNk receptor (IFNkR) in cutaneous lupus erythematosus (CLE) and other inflammatory skin disorders.
(a) Representative immunohistological micrographs of skin specimens of patients with chronic discoid LE (CDLE), subacute CLE (SCLE), and healthy controls
(HCs) stained for the lesional expression of IFNl and the IFNlR (scale bar¼ 100mm). (b) In vivo expression of IFNl and the IFNlR in additional inflammatory
skin diseases, including atopic dermatitis (AD), psoriasis (Pso), lichen planus (LP), and dermatomyositis (DM) (scale bar¼100 mm). (c, d) Semiquantitative
analysis of the expression of (c) IFNl and the (d) IFNlR in healthy controls, CDLE, SCLE, and other inflammatory skin diseases. Shown is the mean staining
intensity within the subsets±SEM. Statistical analyses were performed using the Mann–Whitney U-test (*Po0.05, **Po0.01; NS, not significant).
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the majority of patients with active CLE showed elevated
IFNl1 serum levels. The highest levels were found in patients
with widespread skin lesions. A comparison of patients
with disseminated CDLE lesions and patients where the
disease was limited to one body region (localized CDLE)
supported the notion that the extent of the disease correlates
with the IFNl1 serum levels. In one representative patient
with exacerbated disseminated CDLE, we followed the
IFNl1 serum levels over a time period of 1 year (Figure 2b).
These levels declined parallel to the clinical remission
following systemic treatment with corticosteroids and
hydroxychloroquine.
Production of IFNk1 by human keratinocytes following
TLR stimulation
Our immunohistological analyses demonstrated IFNl expres-
sion in CLE particularly within the epidermis, suggesting that
keratinocytes might be the producers of this cytokine in vivo.
To verify this hypothesis, we investigated IFNl expression in
epidermal explants in vitro. Because immunostimulatory
nuclear acids are thought to induce IFN expression in LE
through TLR activation (Ronnblom and Pascual, 2008) and as
TLR stimulation also induces type III IFNs (Ank et al., 2008),
we exposed epidermal explants to synthetic immunostimu-
latory nucleic acids (double-stranded RNA/polyriboinosinic
polyribocytidylic acid (polyIC) and double-stranded DNA/
CpG-oligodeoxynucleotide). polyIC induces expression of
the IFNl1 protein in the explanted epidermal sheets
(Figure 3a). The immunohistochemical studies were con-
firmed by ELISA analyses, which revealed a significantly
enhanced concentration of IFNl1 (Po0.01) in the culture
supernatant (Figure 3b). Interestingly, polyIC treatment of the
epidermal explants did not induce detectable amounts of
IFNa, IFNb, and IFNg.
Further evidence was obtained with cultured human
keratinocytes. As shown in Figure 3c, IFNl1 was secreted
into the culture supernatant following stimulation with
polyIC. Again, only very low levels of IFNa and IFNb were
detected. Analyses of vesicular stomatitis virus-infected
keratinocytes and detection of CXCL10 levels served as
positive controls (Lebre et al., 2007; Ank et al., 2008).
Additional semiquantitative reverse transcriptase-PCR ana-
lyses demonstrated increased expression levels of both IFNl1
and the IFNlR in polyIC-treated human keratinocytes, and
also in vesicular stomatitis virus-infected cells (Figure 3d). In
accordance with our immunohistological analyses, we found
that IFNlR mRNA was constitutively expressed at low levels
in unstimulated keratinocytes.
IFNk treatment of keratinocytes induces the expression of
proinflammatory cytokines
It has been reported that keratinocytes express the IFNlR and
respond to IFNl stimulation by phosphorylation of STAT1
and upregulation of the major histocompatibility complex I
(Witte et al., 2009). Therefore, we hypothesized that IFNl
might have an autocrine proinflammatory effect on keratino-
cytes. Indeed, exposure of human keratinocytes to recombi-
nant IFNl1 significantly enhanced the secretion of IL6, IL8,
CCL3, and CXCL9 into the culture supernatant (Figure 4a).
However, IFNl1 treatment had no effect on CXCL10
production by cultured keratinocytes.
Culture supernatants of IFNk1-stimulated keratinocytes drive
the recruitment of peripheral blood mononuclear cells (PBMCs)
To investigate the relevance of type III IFNs on the
recruitment of immune cells, we subsequently tested the
functional effect of culture supernatants harvested from
stimulated and unstimulated keratinocytes on the migration
of PBMCs in an in vitro transwell system. As demonstrated in
Figure 4b, supernatants of IFNl1-treated keratinocytes had a
significantly higher capacity to recruit PBMCs than untreated
controls. Supernatants of polyIC-stimulated keratinocytes
served as positive controls.
IFNk and the IFNk-inducible proteins CXCL9, MxA and, IFI27
show a similar epidermal expression pattern in CLE skin lesions
We previously reported differences in the epidermal expres-
sion pattern of the chemokines CXCL9 and CXCL10 in CLE
skin lesions (Wenzel et al., 2007). CXCL9 is typically
expressed within the whole epidermis, whereas CXCL10 is
predominantly found in basal epidermal areas in CLE skin
lesions with an extensive interface dermatitis. Based on our
observation that CXCL9 but not CXCL10 was produced by
IFNl1-treated keratinocytes in vitro, we hypothesized that
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Figure 2. Serum levels of IFNk1 in patients with cutaneous lupus
erythematosus (LE). (a) Shown are IFNl1 serum levels in individual patients
with localized chronic discoid LE (lCDLE), disseminated chronic discoid LE
(dCDLE), subacute cutaneous LE (SCLE), and healthy controls (HCs). The bars
indicate the mean value of the different subsets (**Po0.01; Mann–Whitney
U-test). (b) Clinical findings and IFNl1 serum levels in a representative patient
with dCDLE before and after treatment.
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the individual expression pattern of these chemokines might
correlate with that of IFNl and IFNa. In support of this idea, we
analyzed the CLE skin samples by immunohistochemistry for
the expression pattern of IFN-inducible proteins, including
MxA, IFI27, CXCL9, and CXCL10, and the expression of type I
and type III IFNs. As depicted in Figure 5, CXCL9 and IFNl
were coexpressed in the whole epidermis. The same was true
for MxA and IFI27, the antiviral proteins that are induced by
both type I and type III IFNs (Doyle et al., 2006; Mordstein et al.,
2008). CXCL10, which is not induced by type III IFNs, was only
found along the dermo-epidermal junctional zone. In these
areas, CD3þ effector T cells, which have been shown to carry
CXCL10 within their cytotoxic granules (Wenzel et al., 2007), as
well as blood dendritic cell antigen 2 (BDCA2)þ pDCs were
found along with an expression of IFNa. Thus, the expression
pattern of CXCL9 correlates with that of IFNl, and the pattern of
CXCL10 with that of IFNa.
DISCUSSION
Our observations provide several lines of evidence that
keratinocyte-derived IFNl has a role in the pathophysiology
of CLE. First, IFNl was strongly expressed in the epidermis of
CLE skin lesions. Second, enhanced IFNl1 levels could be
measured in the serum of patients with active disease. Third,
the lesional expression pattern of IFNl correlates with that of
the IFNl-inducible chemokine CXCL9, compatible with the
notion that IFNl drives the inflammatory recruitment of
immune cells. Based on our in vitro studies with explanted
epidermal sheets, cultured keratinocytes, and cell migration
analyses, it is highly plausible that the IFNl1 in CLE patients
derives from keratinocytes and supports the formation of
inflammatory skin lesions.
Originally, the type III IFNs were discovered because of
their antiviral function. The observation that the loss of
antiviral protection in IFNab-receptor-deficient mice is
variable for different viruses prompted a search for comple-
mentary antiviral systems (Kotenko et al., 2003). This led to
the identification of the type III IFN system consisting of
IFNls and the IFNlR that share many antiviral functions with
the type I IFN system. Importantly, IFNl was found to mainly
act on epithelial cells and appears to have a critical role in
epithelial antiviral defense (Sommereyns et al., 2008). For
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Figure 3. Induction of IFNk1 expression in explanted epidermal sheets and cultured primary human keratinocytes. (a, b) Explanted epidermal sheets (n¼ 5)
were stimulated with polyIC and CpG-oligodeoxynucleotide (CpG-ODN). (a) Depicted are representative immunohistological micrographs of epidermal IFNl
expression in untreated (top) and polyIC-treated (bottom) specimens (original magnification 400, scale bar¼100 mm). (b) Shown is the mean concentration
(±SEM) of IFNa, IFNb, IFNg, and IFNl1 in the supernatants of stimulated and unstimulated (CTR) cultures after 24 hours (n¼ 5, **Po0.01). (c, d) Primary
human keratinocytes were stimulated with polyIC (n¼6), or infected with vesicular stomatitis virus (VSV) (n¼ 5). (c) Shown is the mean concentration (±SEM)
of IFNa, IFNb, IFNl1, and CXCL10 in the supernatants of stimulated and unstimulated cultures (**Po0.01; Mann–Whitney U-test). (d) Representative result of a
reverse transcriptase-PCR (RT-PCR) analysis of IFNl1 and IFNl receptor (IFNlR) mRNA expression in untreated, polyIC-stimulated, and VSV-infected
keratinocyte cultures over time.
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example, IFNl treatment prevents herpes simplex virus
type 2 replication in the vaginal mucosa more effectively
than IFNa (Ank et al., 2008). In accordance with these
observations, we found that keratinocytes are able to produce
considerable amounts of IFNl1 after infection with vesicular
stomatitis virus and also following incubation with polyIC,
which imitates a viral infection and activates the innate
immune system through TLR3 and melanoma differentiation-
associated gene 5 (MDA5; Gitlin et al., 2006). Interestingly,
we observed that stimulated keratinocytes produce high
levels of IFNl1, but only low levels of IFNa, IFNb, and IFNg,
suggesting that IFNl is a major IFN of human epidermal cells
in direct response to viral stimuli.
In recent years, it has been demonstrated that type I IFNs,
the major antiviral defense system of the body, have an
important role in the pathophysiology of both SLE and CLE
(Ronnblom et al., 2006; Wenzel and Tuting, 2007). High
IFNa serum levels, which are characteristic for acute viral
infections, have also been observed in acute SLE. Evidence
has accumulated that the activation of the type I IFN system
in SLE involves the stimulation of TLR7 and 9 through DNA/
RNA-autoantibody complexes, thereby imitating the process
that alerts the immune system to the presence of viral nucleic
acids (Ronnblom and Pascual, 2008). Our results provide
evidence that activation of the type III IFN system in the
epidermis not only provides tissue-specific antiviral defense
but also supports the lesional inflammation in CLE. A role for
the type III IFNs in this autoimmune disease is further
supported by our findings in related skin disorders. We also
found IFNl to be expressed in lichen planus and dermato-
myositis skin samples, two autoimmune diseases that share
several features with CLE, particularly the histological
‘‘interface-pattern’’ (Wenzel and Tuting, 2008), but not in
other inflammatory dermatoses such as atopic dermatitis
and psoriasis.
We hypothesize that IFNl induction might represent an
early step in the complex proinflammatory network in CLE.
Our results demonstrate that IFNl induces the epithelial
expression of CXCL9 but not CXCL10, and importantly
CXCL9 has been shown to be the functionally most relevant
CXCR3 ligand for the induction of SLE in an experimental
mouse model (Menke et al., 2008). IFNl-mediated CXCL9
expression might represent an early-step LE skin disease by
supporting the recruitment of CXCR3þ ‘‘natural type I
IFN-producing’’ pDCs and cytotoxic T cells toward the
epidermis (Yoneyama et al., 2004). pDCs produce IFNa and
cytotoxic T cells IFNg at the dermo-epidermal junction,
which both induce the expression of CXCL10 in keratinocytes
(Meller et al., 2005; Wenzel et al., 2005b), which further
drives the typical interface dermatitis (Wenzel and Tuting,
2008). In this way, the type III IFNs may interconnect with the
type I IFNs in the pathophysiology of CLE. It remains tempting
to speculate which signals are responsible for the induction of
IFNl expression in CLE in vivo. As we detected the most
extensive expression of IFNl and the IFNlR in the sun-
exposed skin of SCLE patients, it is conceivable that UV-
induced DNA damage may be involved. Uncleared apoptotic
nuclear material, which is also released following cytotoxic
destruction of keratinocytes, might lead to IFN activation and
fuel the lesional inflammation in CLE (Kuhn and Bijl, 2008).
In conclusion, our results provide evidence that activation
of the type III IFN system in the epidermis supports the
lesional inflammation not only in acute viral infection (Ank
et al., 2008), but also in specific autoimmune diseases,
particularly in CLE.
PATIENTS AND METHODS
Patients and healthy donors
Punch biopsies (4mm) were taken in stages of active skin
disease from 16 patients with CLE. From the two major
disease subsets, CDLE and SCLE, eight patients each were
selected. Additionally, skin biopsies of other chronic inflam-
matory skin diseases (atopic dermatitis, psoriasis, lichen
planus, and dermatomyositis, n¼ 5, respectively) were
analyzed for control purposes. Healthy control specimens
were obtained from the unaffected skin of six patients
undergoing cosmetic surgery. The remaining control skin
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Figure 4. IFNk1 stimulation of human keratinocytes induces the secretion of
proinflammatory cytokines and mediates immune cell migration. (a) Primary
human keratinocytes were stimulated with recombinant IFNl1. Shown is the
mean concentration (±SEM) of IL6, IL8, CCL3, CXCL9, and CXCL10
(chemokine (C-X-C motif) ligands 9 and 10) in supernatants of IFNl1-treated
and untreated cultures after 24 hours (n¼ 5, *Po0.05, **Po0.01; NS, not
significant). (b) The migratory effect of supernatants harvested from IFNl1-
and polyIC-stimulated keratinocytes on the recruitment of peripheral blood
mononuclear cells (PBMCs) was analyzed in an in vitro transwell system.
Depicted is the mean migratory index (¼ specifically migrated/unspecifically
migrated cells)±SEM of five independent biological replicates.
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material was used to isolate primary human keratinocytes.
Additionally, blood serum samples taken from patients with
active CDLE (n¼ 18) or SCLE (n¼ 10) and healthy donors
(n¼8) were included. The study was performed in accor-
dance with the Declaration of Helsinki Principles after
approval by the local regulatory committee (BN 09004). All
patients signed an informed consent.
Histology and immunohistology
Sections were prepared from formalin-fixed and paraffin-
embedded skin biopsies. Standard hematoxylin and eosin
and periodic acid schiff staining were performed for
diagnostic purposes. The lesional expression of IFNl and
the IFNlR was analyzed by immunohistochemistry using
antibodies specific for IL28/29 (sc-66933; Santa Cruz, Santa
Cruz, CA) and the IFNlR (HPA017319; Sigma, Steinheim,
Germany). Additionally, the following monoclonal antibo-
dies were used: MxA (M143, Professor Haller, University of
Freiburg, dilution 1:100), CXCL9 (MAB392; R&D Systems,
Minneapolis, MN), CXCL10 (33 036, R&D), BDCA2
(DDX0043; Dendritics, Lyon, France), CD3 (F7238; Dako,
Hamburg, Germany), and IFNa (MMHA-2; R&D Systems).
Visualization was performed using the CSA II or the LSAB2
staining kit with fast red as chromogen (both from DAKO),
following the manufacture’s instructions. Appropriate iso-
type-specific control antibodies were included. Staining
intensity was graded on a scale from 0 (no staining) to 3
(intense staining) as described before (Wenzel et al., 2005b).
Preparation of explanted epidermal sheets and primary
keratinocyte cultures
To obtain epidermal explants skin specimen, a 4-mm
diameter punch biopsy was taken from skin samples of
healthy patients undergoing plastic surgery. After incubation
for 24 hours at 4 1C in 2.4U dispase (Becton Dickinson,
Heidelberg, Germany), the epidermis was carefully separated
from the dermis. The explanted epidermal sheets were
cultured and stimulated in keratinocyte serum-free growth
medium (KGM2; Promocell, Heidelberg, Germany) supple-
mented with 100 unitsml–1 penicillin and 100 mgml–1 strep-
tomycin using 96-well plates. Alternatively, epidermal sheets
were incubated for 15minutes at 37 1C in 0.2% trypsin and
0.01% EDTA in phosphate-buffered saline to obtain a single-
cell suspension. The trypsin-digest was stopped with RPMI
10% fetal calf serum and cells were seeded in primary culture
at 1.5106 cells per 75 cm2 tissue culture flask. Subse-
quently, cells were subcultured at a density of 5104 cells
per 75 cm2 flask and grown until 80% confluence. All cells
were cultivated at 37 1C and 5% CO2 atmosphere.
Reagents for immune activation
Recombinant IFNa2b (1,000Uml–1; Intron A, Schering,
Berlin, Germany), recombinant IFNl1 (100 ngml–1; R&D),
polyIC (20 mgml–1; Sigma), and CpG-oligodeoxynucleotide
2216 (3 mgml–1, MWG-BIOTECH AG, Ebersberg, Germany)
were used to stimulate explanted epidermal sheets and
cultured keratinocytes in vitro.
Virus infection
Keratinocytes were infected with vesicular stomatitis virus
(RNA virus of the family Rhabdoviridae) for 1 hour (multi-
plicity of infection¼ 1), washed twice, and then incubated
in keratinocyte medium (KGM2). Total cellular RNA was
isolated at different time points (2–24 hours) after infection for
reverse transcriptase-PCR analyses, and the culture super-
natant was collected for ELISA (24 hours).
Quantitative reverse transcriptase-PCR
Explanted epidermal sheets and cultured keratinocytes were
harvested at 4h–72 hours after stimulation and total RNA was
isolated using the NucleoSpin RNA XS according to the
instructions of the manufacturer (Macherey-Nagel, Du¨ren,
Germany). Reverse transcription was performed using the
SSIII system (Invitrogen, Karlsruhe, Germany) and random
primers. Semiquantitative reverse transcriptase-PCR was
performed with the following primers: IFNa (F 50-GAT
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Figure 5. In vivo expression pattern of type I and type III IFN-inducible proteins in cutaneous lupus erythematosus (CLE) skin lesions. Depicted are
representative immunohistological micrographs of an active chronic discoid lupus erythematosus (CDLE) skin lesion stained for CXCL9 and CXCL10,
IFNl, MxA, IFI27, BDCA2, IFNa, and CD3 (original magnification  200, scale bar¼ 100mm). Similar results were detected in tissue samples from
eight different patients with CDLE and subacute CLE (SCLE).
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GGTTTCAGCCTTTTGGA-30; R 50-GCTCACCCATTTCAACC
AGT-30), IFNb (F 50-TCATGAGTTTTCCCCTGGTG-30, R 50-G
ATGCTCCAGAACATCTTTGC-30), IFNl1 (F 50-GCCATGGCT
GCAGCTTGGAC-30; R 50-GGTGGACTCAGGGTGGGTTGA
C-30), IFNlR (F 50-ACCTATTTTGTGGCCTATCAGAGCT-30; R
50-CGGCTCCACTTCAAAAAGGTAAT-30), and GAPDH (F 50-
CCACATCGCTCAGACACCAT-30; R 50-GGCAACAATATCCA
CTTTACCAGAGT-30) as a housekeeping gene. Each analysis
was performed with at least four biological replicates.
Cytokine measurement
IFNa, IFNb, IFNg, IFNl, and CXCL10 proteins were
measured in cultured supernatants using commercially avail-
able sandwich ELISAs following the instructions provided by
the manufacturers (R&D Systems and PBL, Piscataway, NJ).
IL6, IL8, and CXCL9 were detected using the Flow Cytomix
bead assay according to the manufacturer’s instructions
(Bender MedSytems, Vienna, Austria), including data analysis
with FlowCytomix Pro2.2 software (Bender MedSystems,
Vienna, Austria).
Immune cell migration assays
Cell migration assays were performed with PBMCs in 24-well
plates with transwell inserts of 5 mm pore size as described
before (Wenzel et al., 2005a). 5 105 cells were plated
on the cover membrane in RPMI-1640 medium containing
0.4% fetal bovine serum. Culture supernatants of stimulated
(IFNl1: 100 ngml–1; polyIC: 20 mgml–1) and unstimulated
keratinocytes were placed in the bottom chamber. For
determination of the migratory index, 50 ml of the cells
that had migrated to the lower well after 2 hours at 37 1C
were collected in TruCOUNT tubes (Becton Dickinson,
Heidelberg, Germany) and analyzed by flow cytometry.
The absolute number of investigated cells in the samples was
determined by comparing the relative count of investigated
PBMCs by the relative count of fluorescence beads,
using the following equation: (number of events in region
containing cells/number of events in absolute count bead
region) (absolute number of beads per test/test volu-
me)¼ absolute count of cells per volume. The migratory
index was evaluated by dividing specifically migrated cells
(‘‘stimulation’’) by unspecifically migrated cells (‘‘control’’).
Five independent biological replicates were performed.
Statistical procedures
All statistical analyses were performed with SPSS software
(Chicago, IL), (version 17) using the nonparametrical
Mann–Whitney U-test. Probabilities of o0.05 were consi-
dered to be significant (*), and P-values of o0.01 as highly
significant (**).
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